Investors |

News

11 July

LexaGene completes C$5.75 Million Bought Deal Financing. Underwriters Exercise Over-Allotment Option in Full.

Read More

18 June 2018

LexaGene names medical device veteran Joseph Caruso to Board of Directors. Mr. Caruso was responsible for the successful worldwide commercial launch of dozens of medical devices over his 30-year career.

Read More

06 June 2018

LexaGene announces a collaboration with Texas A&M Veterinary Medical Diagnostics Laboratory to begin testing canine dog urine samples on LexaGene’s LX6 prototype.

Read More

29 May 2018

LexaGene has entered into an agreement with the Stanford University School of Medicine to incorporate cancer sequencing technology into a new product.

Read More

15 May 2018

LexaGene announces that its prototype for more effective pathogen detection is now generating data, and is capable of identifying E. coli and Staph.

Read More

04 April 2018

LexaGene has entered into a collaboration with Ethos Veterinary Health to begin testing canine dog urine samples on LexaGene’s LX6 prototype.

Read More